NPIL Pharma to Expand Capacity

NPIL Pharma, the custom manufacturing division of Nicholas Piramal India Ltd. (NPIL; Mumbai), says it will invest about $4 million in its early phase pharma development and scale-up (PDS) facility at Chennai, southern India. NPIL is India’s fourth-largest pharmaceutical company. NPIL says it will add eight new reactors with 12,000 liters of capacity to its Chennai cGMP plant by year-end. New facilities will be installed for manufacturing final active pharmaceutical ingredients (API), with a clean room for final API powder processing and packing. A new...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers